BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) Receives Average Recommendation of “Moderate Buy” from Brokerages

Posted by Brenda Bartman on Sep 26th, 2026

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the six analysts that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $35.00.

BLSM has been the topic of a number of recent analyst reports. Lifesci Capital began coverage on BlossomHill Therapeutics in a report on Tuesday, September 1st. They set an “outperform” rating and a $32.00 price target on the stock. Leerink Partners lifted their target price on BlossomHill Therapeutics from $36.00 to $40.00 and gave the stock an “outperform” rating in a research report on Monday, September 21st. Guggenheim lifted their price objective on shares of BlossomHill Therapeutics from $30.00 to $40.00 and gave the company a “buy” rating in a report on Monday. Zacks Research upgraded BlossomHill Therapeutics to a “hold” rating in a research note on Wednesday, September 2nd. Finally, JPMorgan Chase & Co. started coverage on BlossomHill Therapeutics in a research note on Tuesday, September 1st. They issued an “overweight” rating and a $28.00 target price on the stock.

Check Out Our Latest Research Report on BLSM

BlossomHill Therapeutics Price Performance

BLSM stock opened at $19.75 on Friday. BlossomHill Therapeutics has a fifty-two week low of $15.25 and a fifty-two week high of $27.99.

BlossomHill Therapeutics (NASDAQ:BLSM – Get Free Report) last released its earnings results on Friday, September 18th. The company reported ($8.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by ($7.91). Research analysts expect that BlossomHill Therapeutics will post -3.86 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Bihua Chen bought 312,500 shares of the company’s stock in a transaction on Monday, August 10th. The stock was bought at an average cost of $16.00 per share, with a total value of $5,000,000.00. Following the transaction, the director directly owned 3,614,034 shares in the company, valued at $57,824,544. The trade was a 9.47% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel Vincent Liptak purchased 2,200 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was purchased at an average price of $16.00 per share, with a total value of $35,200.00. Following the purchase, the general counsel directly owned 111,412 shares of the company’s stock, valued at $1,782,592. The trade was a 2.01% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders acquired 1,573,900 shares of company stock worth $25,181,900.

BlossomHill Therapeutics Company Profile

(Get Free Report)

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.